- HMS Community Values
- Introduction to Clinical Research Training
- Letter from the Chairman
- Medical Education
- Dean for Medical Education
- Financial Aid
- Student Services
- Office of Student Affairs
- Academic Societies at HMS
- Scholars in Medicine (SIM)
- Multicultural Affairs
- A View of Student Life
- Career Advising - Roadmap to Residency
- MD Programs
- Student Handbook
- Education Matters
- Student Profiles
- Curriculum Services
- The Academy at Harvard Medical School
- Program Evaluation and Student Assessment
- Anatomical Gift Program
- Teaching Awards
- Application Form and Instructions
- United Kingdom Clinical Scholars Research Training
- Award Listing
- Vanderbilt Hall
- Award Summaries
- Financial Aid
- Spring Preview
- Frequently Asked Questions
- Office of the Registrar
- Award Recipients
- Campus Planning and Facilities
- Ombuds Office
- Research Administration Contacts
- Committee on Microbiological Safety
- Contact Us
- Human Resources
- The Academy
- Office for Academic and Clinical Affairs
- Joint Committee on the Status of Women
- Global Health Research Core
- Global Clinical Scholars Research Training Program
- HMA Standing Committee on Animals
- Office of Research Compliance
- Harvard Medical School Event Calendar
- Office of Diversity RIA Program
- The Dean's Perspective
- Department of Pathology
- Harvard Mahoney Neuroscience Institute
- OHRA Home
- Office of Research Subject Protection
- Alumni Association
- Cancer Biology & Therapeutics Program
- Celiac Program
- Department of Medicine
- HMS Information Technology
- HMS TransMed Program
- Introduction to the Practice of American Medicine
- Office of Communications & External Relations
- Big Data In Healthcare
- Institutional Planning and Policy
- Master of Medical Sciences In Clinical Investigation
- Office of Global Education
- Portugal Clinical Scholars Research Training Program
- Safety Quality Informatics and Leadership
- South American Clinical Research Training Program | SACRT
- Southeast Asia Leadership Program
- Shenzhen-HMS Initiative in International Education
- Contact @HMS
- Office of Global Education
- Human Resources
- Jobs @ HMS
- Dental Medicine
- Harvard University
- Contact us
Diagnosis and treatment decisions for a recently recognized type of children’s brain tumor should be improved by the discovery of the genetic mechanism that causes it, say researchers at Harvard Medical School and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center who identified the unusual DNA abnormality in angiocentric gliomas.
Currently there is no definitive pathological test to help identify this rare type of low-grade glioma. Named for their curious behavior of “hugging” blood vessels in the brain, angiocentric gliomas are usually cured with surgery and don’t need further treatment with radiation or chemotherapy. But given their recent description and difficulties in identifying them confidently, some patients receive the additional therapy, which often is damaging to the growing brain, in an effort to prevent a recurrence.
“Now we know these angiocentric gliomas have a different biology, and we have an exact way of identifying them so that patients can avoid this additional therapy that has life-long consequences,” said Rameen Beroukhim, HMS assistant professor of medicine at Dana-Farber Cancer Institute and a senior author of the report in Nature Genetics. Co-authors of the report include Keith Ligon, HMS associate professor of pathology at Dana-Farber/Boston Children’s, and Adam Resnick, an investigator at Children’s Hospital of Philadelphia.
Angiocentric gliomas were recognized as distinct entities less than 10 years ago. Their name reflects the tumor cells’ tendency to line up around blood vessels. Fewer than 30 cases have been described in medical literature. Seizures are typically the first symptom leading to diagnosis. Although they are classified as a tumor, they are not malignant and don’t spread to other parts of the body.
These rare tumors fall under the umbrella of pediatric low-grade gliomas (PLGG), which collectively are the most common pediatric brain tumor. Until now, no specific genetic abnormality had been identified as a “driver” of angiocentric gliomas.
In the current study, the researchers analyzed data from 249 PLGG tumors, including 19 angiocentric gliomas, and discovered an unusual genetic accident as the fundamental cause of the angiocentric gliomas. The culprit event is a shuffling of DNA segments that brings together two separate genes, MYB and QKI, which become joined, or fused. MYB is a “proto-oncogene,” a normal gene that can become a cancer-causing oncogene. QKI is a tumor-suppressor gene that normally functions to prevent cells from becoming malignant.
When these two genes are abnormally joined, the researchers found, it triggers not one but the following three different mechanisms that converge to produce a tumor.
- Epigenetic control elements called enhancers are “hijacked” and brought closer to the MYB gene, which increases MYB activity.
- The MYB-QKI fusion gene causes cells to make a protein that binds to another control element—a promoter—that also revs up MYB activity, prodding the cells into runaway growth.
- The rearrangement also knocks out one of the two copies of the QPI tumor suppressor gene, enabling cancer-related genes to escape control and contribute to tumor formation.
“This represents the first example of a single driver rearrangement simultaneously transforming cells via three genetic and epigenetic mechanisms in a cancer,” the authors wrote. They identified this specific abnormality as “a defining event” found only in the angiocentric gliomas—it was not present in any of the other pediatric low-grade gliomas examined in the study.
Because of these findings, the researchers said, angiocentric glioma should be classified as a separate biologic entity, with the presence of the gene fusion confirming the diagnosis. “This could aid in distinguishing angiocentric glioma from tumors with higher potential for recurrence that could require further treatment,” they said. The authors have developed the first genetic test now available for these patients through collaboration with cytogeneticist Azra Ligon, HMS associate professor of pathology at Brigham and Women’s Hospital and Dana-Farber.
The research was supported by A Kids’ Brain Tumor Cure Foundation (PLGA Foundation) and National Institutes of Health grants R01NS085336 and PO1CA142536.
Adapted from a Dana-Farber Cancer Institute news release.
Stay informed via email on the latest news, research, and
media from Harvard Medical School.